Treatment of relapsed/refractory MM patients with single agent ABT‐199 revealed an acceptable safety profile and evidence of activity in patients; especially those with a t(11;14) translocation and those with a favorable Bcl‐2 family profile.33 MM cell lines and primary myeloma cells bearing the t(11;14) translocation were particularly sensitive to ABT‐199. This evidence concerns the gene BCL2 and Miyoshi myopathy.